Brief: Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
04/06/2024 13:35
June 4 (Reuters) - Cue Biopharma Inc CUE.O :
* CUE BIOPHARMA PRESENTS UPDATED DATA FROM PHASE 1 TRIAL OF
CUE-101 IN RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER AT THE
2024 ASCO ANNUAL MEETING
Source text for Eikon: ID:nGNX9909sg
Further company coverage: CUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cue Biopharma
See all newsU.S. STOCKS ON THE MOVE-Insmed, Marvell, Meta
US STOCKS ON THE MOVE-Meta, Marvell Technology, Insmed
U.S. STOCKS ON THE MOVE-Accenture, Arhaus, Alkermes
Cue Biopharma surges after positive results from mid-stage study for CUE-221
Brief: Cue Biopharma Announces Positive Topline Results From Cue-221 Phase 2 Study In Chronic Spontaneous Urticaria